William Blair Forecasts Genmab A/S FY2027 Earnings

Key Points

• William Blair forecasts Genmab A/S will achieve earnings per share (EPS) of $1.59 for FY2027, which is higher than the consensus estimate of $1.45 for the current full year.
• As of now, Genmab A/S has a market capitalization of $19.35 billion and its stock has a 52-week range between $17.24 and $33.65.
• Analyst ratings for Genmab A/S include two "Strong Buy," six "Buy," and a current average price target of $40.80.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Research analysts at William Blair issued their FY2027 earnings per share (EPS) estimates for shares of Genmab A/S in a research note issued to investors on Monday, October 20th. William Blair analyst M. Phipps expects that the company will post earnings per share of $1.59 for the year. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. William Blair also issued estimates for Genmab A/S's FY2028 earnings at $2.60 EPS.

A number of other brokerages have also commented on GMAB. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Genmab A/S in a research report on Wednesday, October 15th. Wall Street Zen lowered Genmab A/S from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Zacks Research upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, October 2nd. Weiss Ratings restated a "hold (c)" rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Finally, Guggenheim upgraded Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 price target on the stock in a research report on Tuesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Genmab A/S presently has an average rating of "Moderate Buy" and a consensus price target of $40.80.

Genmab A/S Stock Performance

Shares of GMAB opened at $30.13 on Wednesday. The firm has a market capitalization of $19.35 billion, a price-to-earnings ratio of 15.14, a PEG ratio of 1.71 and a beta of 0.98. The business's fifty day moving average price is $28.30 and its two-hundred day moving average price is $23.52. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $33.65.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. The firm had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GMAB. Blue Trust Inc. lifted its holdings in Genmab A/S by 169.9% during the first quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock worth $145,000 after acquiring an additional 4,666 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in Genmab A/S by 20.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 249,468 shares of the company's stock worth $4,885,000 after acquiring an additional 42,361 shares in the last quarter. DAVENPORT & Co LLC lifted its holdings in Genmab A/S by 21.1% during the first quarter. DAVENPORT & Co LLC now owns 31,679 shares of the company's stock worth $620,000 after acquiring an additional 5,529 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in Genmab A/S by 1.7% during the first quarter. Envestnet Asset Management Inc. now owns 736,326 shares of the company's stock worth $14,417,000 after acquiring an additional 12,545 shares in the last quarter. Finally, Callan Capital LLC bought a new position in Genmab A/S during the first quarter worth about $281,000. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.